Clearmind Medicine announces publication of review of MEAI

Clearmind Medicine (CMND) announced the publication of a review article validating the therapeutic promise of its proprietary candidate, MEAI, in combating alcohol use disorder, AUD. Entitled “The Potential Therapeutic Effects of MEAI in the Treatment of Alcohol Use Disorder”, the peer-reviewed review was published on December 2, 2025, in Current Addiction Reports. Highlights from the Review: Recreational users usually take MEAI orally in amounts ranging from 1 to 2 mg/kg body weight per session. They report feeling positive effects within 4 hours, including a decreased desire to drink alcohol, which has been the basis of the potential use of MEAI to prevent excessive drinking; The aminoindane family acts as substrate-type monoamine releasers, showing varying degrees of selectivity for SERT, NET, and DAT; Recreational users of MEAI did not report any serious adverse events, although one individual did not enjoy the experience. There are no published studies on MEAI’s adverse effects in human volunteers, but based on its receptor interactions, MEAI is expected to have less frequent adverse effects and milder toxicity compared to MDMA.